Hyperion DeFi, Inc. (NASDAQ:HYPD) Receives Consensus Rating of “Hold” from Analysts

Shares of Hyperion DeFi, Inc. (NASDAQ:HYPD) have earned an average recommendation of “Hold” from the four brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $5.8750.

Several brokerages have commented on HYPD. Zacks Research upgraded Hyperion DeFi to a “hold” rating in a report on Monday, December 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Thursday, January 22nd. Cantor Fitzgerald initiated coverage on shares of Hyperion DeFi in a report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price objective for the company. Finally, Chardan Capital set a $7.75 target price on shares of Hyperion DeFi and gave the company a “buy” rating in a research note on Wednesday, December 24th.

Insider Transactions at Hyperion DeFi

In other Hyperion DeFi news, CFO David R. Knox acquired 27,950 shares of the company’s stock in a transaction dated Wednesday, December 31st. The shares were acquired at an average cost of $3.59 per share, for a total transaction of $100,340.50. Following the completion of the purchase, the chief financial officer owned 327,950 shares of the company’s stock, valued at approximately $1,177,340.50. This trade represents a 9.32% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ellen R. Strahlman acquired 11,856 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The shares were acquired at an average cost of $3.61 per share, with a total value of $42,800.16. Following the transaction, the director directly owned 34,869 shares in the company, valued at $125,877.09. The trade was a 51.52% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 58,830 shares of company stock valued at $213,424 over the last 90 days. Corporate insiders own 10.86% of the company’s stock.

Institutional Trading of Hyperion DeFi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Formidable Asset Management LLC bought a new position in Hyperion DeFi in the 4th quarter worth approximately $83,000. Nations Financial Group Inc. IA ADV bought a new stake in shares of Hyperion DeFi in the fourth quarter valued at approximately $40,000. Sanctuary Advisors LLC acquired a new stake in shares of Hyperion DeFi in the fourth quarter worth $38,000. Investment House LLC bought a new position in Hyperion DeFi during the fourth quarter worth $166,000. Finally, Geode Capital Management LLC bought a new position in Hyperion DeFi during the fourth quarter worth $214,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

Hyperion DeFi Stock Performance

Shares of NASDAQ HYPD opened at $3.27 on Monday. The business’s 50-day simple moving average is $3.46 and its 200-day simple moving average is $5.38. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. Hyperion DeFi has a 52 week low of $0.85 and a 52 week high of $17.18. The firm has a market cap of $26.72 million, a price-to-earnings ratio of -0.81 and a beta of 2.74.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.